Ratings Astrana Health, Inc.

Equities

ASTH

US03763A2078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
36.72 ^USD	+0.44%		-1.34%	-4.13%

Apr. 24	Astrana Health, Inc. Announces Redesignation of Albert Young from Chief Administrative Officer to A New Role as Senior Vice President of Health Affairs	CI
Apr. 02	Astrana Health Completes Acquisition of Community Family Care Medical Group	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
With regards to fundamentals, the enterprise value to sales ratio is at 0.96 for the current period. Therefore, the company is undervalued.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The firm trades with high earnings multiples: 24.32 times its 2024 earnings per share.
The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ASTRANA HEALTH, INC.	-4.13%	1.77B		D+
CVS HEALTH CORPORATION	-14.92%	84.68B		B-
HCA HEALTHCARE, INC.	+13.30%	81.12B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B		B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B		A-
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B		A-
PURE HEALTH HOLDING	-31.75%	11.77B	-	-
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B		A-
DAVITA INC.	+27.44%	11.71B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes